Genelux (GNLX) Non Operating Interest Expenses (2022 - 2023)
Genelux (GNLX) posted Non Operating Interest Expenses of $42000.0 for Q3 2023, up 75.0% on a QoQ basis from $24000.0 in Q2 2023, and down 85.31% year-over-year from $286000.0 in Q3 2022.
Powered by 
Analysis
Genelux (GNLX) Non Operating Interest Expenses (2022 - 2023) Analysis & Trends
Genelux has reported Non Operating Interest Expenses for 2 years, with the latest figure at $42000.0 in Q3 2023.
- On a quarterly basis, Non Operating Interest Expenses fell 85.31% year-over-year to $42000.0 in Q3 2023; TTM through Dec 2023 was $3.2 million, a N/A change from a year earlier, with the FY2023 full-year figure at $3.2 million, up 174.09% from the prior year.
- Non Operating Interest Expenses was $42000.0 for Q3 2023 at Genelux, up from $24000.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $3.1 million in Q1 2023, with the low at $24000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 42,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 3.11 Mn |
| Dec 31, 2022 | 291,000.00 |
| Sep 30, 2022 | 286,000.00 |
| Mar 31, 2022 | 288,000.00 |